Oncternal Total Assets from 2010 to 2024

ONCT Stock

USD 1.14 0.02 1.72%

Oncternal Therapeutics Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2003-12-31

Previous Quarter

23.9 M

Current Value

15.6 M

Quarterly Volatility

35.1 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 1.0E-4 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.

Check out the analysis of Oncternal Therapeutics Correlation against competitors.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

Latest Oncternal Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Oncternal Therapeutics over the last few years. Total assets refers to the total amount of Oncternal Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Oncternal Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Oncternal Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncternal Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 36.73 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Oncternal Total Assets Regression Statistics

	Arithmetic Mean	49,253,140
	Geometric Mean	36,338,879
	Coefficient Of Variation	63.71
	Mean Deviation	24,557,216
	Median	46,236,000
	Standard Deviation	31,379,364
	Sample Variance	984.7T
	Range	117.1M
	R-Value	0.37
	Mean Square Error	915.8T
	R-Squared	0.14
	Significance	0.18
	Slope	2,591,528
	Total Sum of Squares	13785.3T

Oncternal Total Assets History

	2024	61.3 M
	2023	36.7 M
	2022	68.7 M
	2021	93.6 M
	2020	118.8 M
	2019	21.7 M
	2018	31.3 M

Other Fundumenentals of Oncternal Therapeutics

Intangibles To Total Assets

Oncternal Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Accounts Payable	Common Stock	Current Deferred Revenue	Intangible Assets	Net Receivables	Short Term Debt	Short Term Investments	Net Tangible Assets	Good Will	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.47	-0.88	0.25	-0.02	1.0	0.24	0.16	-0.46	-0.33	0.1	-0.37	-0.04	0.6	-0.05	-0.37	-0.12	0.82	0.82	0.56
Total Stockholder Equity	-0.47		0.49	-0.5	0.09	-0.47	-0.28	-0.09	0.16	0.15	0.16	0.09	0.11	-0.47	0.2	0.52	0.32	-0.69	-0.68	-0.84
Net Debt	-0.88	0.49		-0.29	0.16	-0.88	-0.17	-0.14	0.39	0.17	-0.16	0.21	0.48	-0.63	0.3	0.37	-0.01	-0.79	-0.79	-0.68
Retained Earnings	0.25	-0.5	-0.29		-0.39	0.24	-0.18	-0.38	-0.53	0.34	-0.37	0.4	-0.16	0.75	0.22	-0.84	0.27	0.41	0.41	0.21
Total Liab	-0.02	0.09	0.16	-0.39		-0.02	-0.39	0.87	0.35	-0.22	0.21	-0.26	0.39	-0.29	-0.13	0.24	-0.3	-0.14	-0.14	-0.06
Total Current Assets	1.0	-0.47	-0.88	0.24	-0.02		0.24	0.16	-0.45	-0.33	0.11	-0.37	-0.04	0.6	-0.06	-0.37	-0.12	0.83	0.83	0.57
Accounts Payable	0.24	-0.28	-0.17	-0.18	-0.39	0.24		-0.34	-0.07	-0.32	-0.14	-0.29	0.04	-0.21	-0.07	0.11	-0.24	0.1	0.09	0.33
Common Stock	0.16	-0.09	-0.14	-0.38	0.87	0.16	-0.34		0.22	-0.15	0.19	-0.24	0.11	-0.11	-0.4	0.25	-0.15	0.06	0.06	0.27
Current Deferred Revenue	-0.46	0.16	0.39	-0.53	0.35	-0.45	-0.07	0.22		-0.31	0.7	-0.27	-0.03	-0.76	-0.29	0.36	-0.51	-0.38	-0.38	-0.13
Intangible Assets	-0.33	0.15	0.17	0.34	-0.22	-0.33	-0.32	-0.15	-0.31		-0.41	0.98	-0.09	0.28	-0.16	0.17	0.85	-0.14	-0.14	-0.06
Net Receivables	0.1	0.16	-0.16	-0.37	0.21	0.11	-0.14	0.19	0.7	-0.41		-0.42	-0.21	-0.31	-0.13	0.12	-0.39	0.03	0.03	-0.07
Short Term Debt	-0.37	0.09	0.21	0.4	-0.26	-0.37	-0.29	-0.24	-0.27	0.98	-0.42		-0.08	0.27	-0.1	0.12	0.77	-0.12	-0.12	-0.06
Short Term Investments	-0.04	0.11	0.48	-0.16	0.39	-0.04	0.04	0.11	-0.03	-0.09	-0.21	-0.08		-0.14	0.47	0.13	-0.15	-0.16	-0.16	-0.28
Net Tangible Assets	0.6	-0.47	-0.63	0.75	-0.29	0.6	-0.21	-0.11	-0.76	0.28	-0.31	0.27	-0.14		0.19	-0.62	0.36	0.67	0.67	0.4
Good Will	-0.05	0.2	0.3	0.22	-0.13	-0.06	-0.07	-0.4	-0.29	-0.16	-0.13	-0.1	0.47	0.19		-0.33	-0.14	-0.1	-0.09	-0.59
Capital Surpluse	-0.37	0.52	0.37	-0.84	0.24	-0.37	0.11	0.25	0.36	0.17	0.12	0.12	0.13	-0.62	-0.33		0.11	-0.37	-0.37	-0.19
Property Plant Equipment	-0.12	0.32	-0.01	0.27	-0.3	-0.12	-0.24	-0.15	-0.51	0.85	-0.39	0.77	-0.15	0.36	-0.14	0.11		-0.18	-0.18	-0.11
Net Invested Capital	0.82	-0.69	-0.79	0.41	-0.14	0.83	0.1	0.06	-0.38	-0.14	0.03	-0.12	-0.16	0.67	-0.1	-0.37	-0.18		1.0	0.67
Net Working Capital	0.82	-0.68	-0.79	0.41	-0.14	0.83	0.09	0.06	-0.38	-0.14	0.03	-0.12	-0.16	0.67	-0.09	-0.37	-0.18	1.0		0.66
Capital Stock	0.56	-0.84	-0.68	0.21	-0.06	0.57	0.33	0.27	-0.13	-0.06	-0.07	-0.06	-0.28	0.4	-0.59	-0.19	-0.11	0.67	0.66

Click cells to compare fundamentals

About Oncternal Therapeutics Financial Statements

Oncternal Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Oncternal Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Oncternal Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oncternal Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	36.7 M	61.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Oncternal Stock Analysis

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC